{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T02:53:23Z","timestamp":1770692003098,"version":"3.49.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Administration of Traditional Chinese Medicine: 2019 Project of building evidence based practice capacity for TCM","award":["No. 2019XZZX-ZL006"],"award-info":[{"award-number":["No. 2019XZZX-ZL006"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Metastatic colorectal cancer (mCRC) causes high cancer-related morbidity and mortality worldwide. Although chemotherapy and targeted agents treatment improve median survival and 5-year survival rates, there is only one-third of patients who adhere to treatment protocol until the pause of disease progression. Hezhong granule is a traditional Chinese herbal formula used for mCRC, which has shown good potential in alleviating the adverse effects of chemotherapy, enhancing the effectiveness of chemotherapy, and improving the quality of life. Therefore, the purpose of the study is to further validate the clinical efficacy and safety of the Chinese herbal medicine formula named Hezhong (HZ) in combination with standard chemotherapy and cetuximab (CET) or bevacizumab (BV) for treating mCRC.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>In this multi-center, randomized, double-blinded, placebo-controlled trial, 360 eligible mCRC patients who will be randomly assigned to Hezhong or placebo group with a 1: 1 ratio. Participants in the Hezhong group will receive standard chemotherapy and CET or BV plus Hezhong Granule until the pause of disease progression, death, the exhibition of intolerable toxicity, or up to 6 months, while the placebo group will treat with standard chemotherapy and CET or BV plus placebo. The primary endpoint is progression-free survival (PFS). The secondary endpoints are overall survival (OS), objective response rate (ORR), safety, quality of life years (QOL), and chemotherapy-induced nausea and vomiting (CINV).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Expected results<\/jats:title>\n<jats:p>The expected results of this trial are to improve the PFS and QOL of patients with mCRC and provide evidence-based recommendations for the treatment of mCRC with traditional Chinese medicine in China.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p>The trial has been registered with the Chinese Clinical Trial Registry (ChiCTR). The trial registration number was <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=41643\" xlink:type=\"simple\">ChiCTR2100041643<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0275058","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T18:31:27Z","timestamp":1671215487000},"page":"e0275058","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of Chinese herbal medicine formula on progression-free survival among patients with metastatic colorectal cancer: Study protocol for a multi-center, double-blinded, randomized, placebo-controlled trial"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-3850","authenticated-orcid":true,"given":"Qiaoling","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuohong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengming","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"issue":"12","key":"pone.0275058.ref001","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2468-1253(19)30345-0","article-title":"The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"4","author":"GBD 2017 Colorectal Cancer Collaborators","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"pone.0275058.ref002","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"E Dekker","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"pone.0275058.ref003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40880-019-0368-6","article-title":"Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics","volume":"39","author":"RM Feng","year":"2019","journal-title":"Cancer Commun"},{"issue":"5","key":"pone.0275058.ref004","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"CF Xia","year":"2022","journal-title":"Chinese Medical Journal"},{"issue":"4","key":"pone.0275058.ref005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/PPO.0000000000000328","article-title":"Antiangiogenic Therapy in Colorectal Cancer.","volume":"24","author":"K Mody","year":"2018","journal-title":"Cancer journal"},{"issue":"3","key":"pone.0275058.ref006","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/1758834015572343","article-title":"Therapeutic strategy in unresectable metastatic colorectal cancer: An updated review.","volume":"7","author":"C Benoist","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"pone.0275058.ref007","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2018.12.019","article-title":"Treatment sequencing in metastatic colorectal cancer","volume":"109","author":"DP Modesta","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"5","key":"pone.0275058.ref008","first-page":"149","article-title":"Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives","volume":"32","author":"F Geng","year":"2017","journal-title":"Cancer Biother Radiopharm"},{"issue":"21","key":"pone.0275058.ref009","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2006.06.1317","article-title":"Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.","volume":"24","author":"R Goldberg","year":"2006","journal-title":"J Clin Oncol"},{"issue":"45","key":"pone.0275058.ref010","first-page":"45","article-title":"The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity","volume":"2","author":"W Lam","year":"2010","journal-title":"Sci Transl Med"},{"issue":"5","key":"pone.0275058.ref011","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5582\/bst.2021.01318","article-title":"The positive role of traditional Chinese medicine as an adjunctive therapy for cancer","volume":"15","author":"XY Zhang","year":"2021","journal-title":"Biosci Trends"},{"issue":"7","key":"pone.0275058.ref012","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0006-2952(03)00011-X","article-title":"Resveratrol-induced g2 arrest through the inhibition of cdk7 and p34cdc2 kinases in colon carcinoma ht29 cells","volume":"65","author":"YC Liang","year":"2003","journal-title":"Bio-chem Pharmacol"},{"issue":"12","key":"pone.0275058.ref013","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1021\/jf800175a","article-title":"Resveratrol induces apoptosis through ros-dependent mitochondria pathway in ht-29 human colorectal carcinoma cells","volume":"56","author":"ME Juan","year":"2008","journal-title":"J Agric Food Chem"},{"issue":"4","key":"pone.0275058.ref014","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/annonc\/mdl465","article-title":"A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity","volume":"18","author":"K Mok T S","year":"2007","journal-title":"Annals of Oncology"},{"issue":"32","key":"pone.0275058.ref015","first-page":"6315","article-title":"Curative Effect of Jianpi Yiqi Jiedu Decoction Combined with Chemotherapy on the Patients with Advanced Colorectal Cancer","volume":"12","author":"YL Fan","year":"2017","journal-title":"Progress in Modern Biomedicine"},{"issue":"3","key":"pone.0275058.ref016","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11655-017-2962-2","article-title":"Efficacy and Safety of Quxie Capsule in Metastatic Colorectal Cancer: A Double-Blind Randomized Placebo Controlled Trial","volume":"24","author":"T Zhang","year":"2018","journal-title":"Chin J Integr Med"},{"key":"pone.0275058.ref017","first-page":"1619809","article-title":"Effect of Xiaoyutang Combined with Intraperitoneal Heat Perfusion Chemotherapy on Immune Function, Circulating mir, Prognosis, and Survival of Postoperative Patients with Colorectal Cancer.","volume":"2021","author":"LX Li","year":"2021","journal-title":"Comput Math Methods Med"},{"key":"pone.0275058.ref018","doi-asserted-by":"crossref","first-page":"618793","DOI":"10.3389\/fonc.2021.618793","article-title":"Effect of PRM1201 Combined With Adjuvant Chemotherapy on Preventing Recurrence and Metastasis of Stage III Colon Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.","volume":"11","author":"R Jia","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"pone.0275058.ref019","doi-asserted-by":"crossref","first-page":"eRW4007","DOI":"10.1590\/s1679-45082018rw4007","article-title":"Chemotherapy protocols and incidence of oral mucositis. An integrative review","volume":"16","author":"M Curra","year":"2018","journal-title":"Einstein (Sao Paulo)."},{"issue":"7","key":"pone.0275058.ref020","first-page":"1523","article-title":"Clinical Study on Banxia Xiexin Decoction in Treatment of Disharmony between Liver and Spleen after Colorectal Cancer Surgery","volume":"12","author":"YJ Li","year":"2017","journal-title":"World Chinese Medicine"},{"issue":"14","key":"pone.0275058.ref021","first-page":"117","article-title":"Clinical Study on Modified Banxia Xiexin Tang Combined with FOLFOX Scheme for Colorectal Cancer.","volume":"53","author":"LM Zhao","year":"2021","journal-title":"Journal of New Chinese medicine"},{"key":"pone.0275058.ref022","author":"D. Liang","year":"2021"},{"key":"pone.0275058.ref023","author":"L. Du","year":"2021"},{"issue":"02","key":"pone.0275058.ref024","first-page":"138","article-title":"Efficacy and mechanism of Xiaobanxia Decoction and categorized formula in preventing and treating delayed chemotherapeutic vomiting","volume":"42","author":"JY Zhao","year":"2020","journal-title":"International Journal of Traditional Chinese Medicine"},{"issue":"07","key":"pone.0275058.ref025","first-page":"611","article-title":"Study on the Preventing and Treating Chemotherapy-Induced Nausea and Vomiting Anti-inflammatory and Anti-inflammatory Effects of Antiemetic Chinese Herbal Medicines.","volume":"37","author":"T Zhang","year":"2018","journal-title":"Shandong Journal of Traditional Chinese Medicine"},{"key":"pone.0275058.ref026","author":"CG Yu","year":"2015"},{"key":"pone.0275058.ref027","first-page":"61","article-title":"Ant-i emetic Effect of Ethanol Extract from \u201cWuzhuyu Broth\u201d","volume":"11","author":"T Zhang","year":"2002","journal-title":"China Journal of Chinese Materia Medica"},{"issue":"5","key":"pone.0275058.ref028","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF00449426","article-title":"A validation study of the domains of the core EORTC quality of life questionnaire","volume":"2","author":"HE Niezgoda","year":"1993","journal-title":"Qual Life Res"},{"key":"pone.0275058.ref029","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","article-title":"Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea?","volume":"20","author":"TL Ng","year":"2015","journal-title":"Oncologist"},{"issue":"2","key":"pone.0275058.ref030","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"11","key":"pone.0275058.ref031","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/DCR.0000000000000618","article-title":"Methodological and reporting quality of comparative studies evaluating health-related quality of life of colorectal cancer patients and controls: a systematic review","volume":"59","author":"CK Wong","year":"2016","journal-title":"Dis Colon Rectum"},{"key":"pone.0275058.ref032","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events. Version 4.0. NCI 2010. Accessed on 28 June 2019."},{"issue":"5","key":"pone.0275058.ref033","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1081\/CNV-200032911","article-title":"Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life, and symptom distress.","volume":"22","author":"SS Hwang","year":"2004","journal-title":"Cancer Invest"},{"key":"pone.0275058.ref034","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3389\/fphar.2020.00478","article-title":"Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.","volume":"11","author":"NN Liu","year":"2020","journal-title":"Front. Pharmacol"},{"issue":"23","key":"pone.0275058.ref035","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer","volume":"350","author":"H Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"16","key":"pone.0275058.ref036","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","article-title":"Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.","volume":"25","author":"JP Kuebler","year":"2007","journal-title":"J Clin Oncol"},{"key":"pone.0275058.ref037","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1002\/cncr.27593","article-title":"Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01","volume":"118","author":"KM Kidwell","year":"2012","journal-title":"Cancer"},{"issue":"19","key":"pone.0275058.ref038","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"T Andr\u00e9","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"pone.0275058.ref039","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s12094-012-0979-8","article-title":"Clinical and T. Oncology: Polymorphism of TS 3\u2019-UTR predicts survival of Chinese advanced gastric; cancer patients receiving first-line capecitabine plus paclitaxel","volume":"15","author":"J Gao","year":"2013","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"pone.0275058.ref040","doi-asserted-by":"crossref","first-page":"e000354","DOI":"10.1136\/esmoopen-2018-000354","article-title":"Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer","volume":"3","author":"M Kotaka","year":"2018","journal-title":"ESMO open"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0275058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T18:32:01Z","timestamp":1671215521000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0275058"}},"subtitle":[],"editor":[{"given":"Sudeep","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0275058","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]}}}